文献速递耳科与耳神经

替妥木单抗致听力障碍的模式:一项系统综述

Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-08-28

该研究系统检索PubMed、EMBASE与Cochrane Library,最终纳入7项研究、109例接受替妥木单抗治疗的患者。最常见症状为听力下降(22%)、耳闷(18%)与耳鸣(14%);有数据者中41%符合耳毒性标准,均表现为中频或更高频率的听阈偏移。作者认为耳毒性可能发生,常规听力筛查联合超高频测试可能有必要,真实发生率仍未知。

要点

  • 接受替妥木单抗治疗者中41%符合耳毒性标准,听阈偏移均位于中频或更高频率。
  • 最常见症状为听力下降(22%)、耳闷(18%)与耳鸣(14%)。
  • 15例(14%)接受超高频听力测试,其中8例(53%,8/15)仅在该频段出现偏移。

核心结论

  • 替妥木单抗治疗患者可能发生耳毒性,听力下降主要位于较高频率,常规听力筛查联合超高频测试可能有必要。
  • 替妥木单抗相关耳毒性的真实发生率仍未知,需更多数据阐明机制并制定降低风险的策略。

研究设计与样本

  • 系统综述,采用标准化方法学,检索PubMed、EMBASE与Cochrane Library。
  • 初检76篇文章,最终纳入7项研究、109例唯一患者。
  • 4项研究为4级证据,1项为3级证据,2项为2级证据;偏倚采用混合方法评价工具评估。

主要发现

  • 平均年龄55±14岁,女性占多数(64%)。
  • 最常见症状为听力下降(22%),其次为耳闷(18%)与耳鸣(14%)。
  • 有可用数据的患者中41%符合耳毒性标准,全部表现为中频或更高频率的听阈偏移。
  • 15例(14%)患者接受超高频听力测试,其中8例(53%,8/15)仅在该频段出现偏移。

临床怎么用

  • 作者认为,在接受替妥木单抗治疗的患者中常规听力筛查联合超高频测试可能有必要。

局限性

  • 替妥木单抗相关耳毒性的真实发生率仍未知。
  • 需更多数据以阐明潜在机制并制定降低风险的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hearing loss has been reported after administration of the monoclonal antibody teprotumumab. The purpose of this study was to review available evidence regarding the patterns of teprotumumab-related ototoxicity. DATA SOURCES: PubMed, EMBASE, and Cochrane Library. REVIEW METHODS: A systematic review was performed using standardized methodology. Studies were included if they included subjects who were prescribed teprotumumab. Exclusion criteria included non-English articles, abstracts, letters/commentaries, case reports, and reviews. Subjects without both pre- and posttreatment audiometric data were also excluded. Bias was assessed using the Mixed Methods Appraisal Tool. RESULTS: From an initial search of 76 articles, 7 studies reporting on 109 unique patients were included. Four studies were level 4 evidence, 1 study was level 3 evidence, and 2 studies were level 2 evidence. Mean age was 55 ± 14 years with a female predominance (64%). The most commonly reported symptoms were hearing loss (22%), followed by fullness (18%) and tinnitus (14%). In total, 41% of patients with available data met criteria for ototoxicity, all exhibiting shifts in the middle frequencies or higher. Fifteen (14%) patients underwent ultrahigh frequency audiometric testing and 8 (53%, 8/15) demonstrated shifts exclusively in this range. CONCLUSION: Ototoxicity may occur in patients treated with teprotumumab. Hearing loss occurs primarily in higher frequencies, and routine hearing screening with ultrahigh frequency testing may be warranted. The true incidence of ototoxicity with teprotumumab remains unknown, and more data is needed to elucidate underlying mechanisms and develop strategies to minimize risks.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Wong K, Arya P, Salmeron Y, et al. Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review. Otolaryngol Head Neck Surg. 2024. PMID: 39194388. doi:10.1002/ohn.955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。